The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.
 
Edward B. Garon
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Roy S. Herbst
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; NovaRX; pfizer
Consulting or Advisory Role - Biothera; DiaTech Oncology; Endocyte; Kolltan Pharmaceuticals; N-of-One
Research Funding - Genentech/Roche
 
Dong-Wan Kim
No Relationships to Disclose
 
Enriqueta Felip
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Roche
 
Jose Luis Perez-Gracia
Research Funding - Merck Sharp & Dohme
 
Ji-Youn Han
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
Consulting or Advisory Role - Novartis
Speakers' Bureau - AstraZeneca; Roche
Research Funding - AstraZeneca; Boehringer Ingelheim; Roche
 
Julian R. Molina
No Relationships to Disclose
 
Joo-Hang Kim
Research Funding - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Roche
 
Catherine Dubos Arvis
No Relationships to Disclose
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Research Funding - AstraZeneca
 
Margarita Majem
No Relationships to Disclose
 
Mary J. Fidler
No Relationships to Disclose
 
Matthew A. Gubens
Consulting or Advisory Role - ARIAD; Boehringer Ingelheim; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Nektar; Pfizer
Research Funding - Abbvie (Inst); Celgene (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); OncoMed (Inst)
Travel, Accommodations, Expenses - Celgene; Genentech/Roche
 
Gilberto Castro
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Eurofarma; Pfizer; Teva
Speakers' Bureau - AstraZeneca; Bayer; Eurofarma; Lilly; Merck Serono; Novartis; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Boehringer Ingelheim; Eurofarma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
 
Marcelo Garrido
No Relationships to Disclose
 
Yue Shentu
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Ellie Im
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Gregory M. Lubiniecki
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Paul Baas
Honoraria - AstraZeneca; Verastem
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme